Sagimet Biosciences Inc. beat EPS estimates 100% of the time across 10 reported quarters (10 beats, 0 misses), averaging +22.3% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.28 | $-0.26 | +7.1% | Beat | |
| Q1 FY26 | $-0.39 | $-0.33 | +15.4% | Beat | |
| Q4 FY25 | $-0.43 | $-0.29 | +32.6% | Beat | |
| Q3 FY25 | $-0.41 | $-0.40 | +2.4% | Beat | |
| Q2 FY25 | $-0.52 | $-0.32 | +38.5% | Beat | |
| Q1 FY25 | $-0.79 | $-0.56 | +29.1% | Beat | |
| Q4 FY24 | $-0.65 | $-0.50 | +23.1% | Beat | |
| Q3 FY24 | $-0.47 | $-0.45 | +4.3% | Beat | |
| Q2 FY24 | $-0.34 | $-0.25 | +26.5% | Beat | |
| Q1 FY24 | $-0.41 | $-0.23 | +43.9% | Beat | |
| Q3 FY23 | not reported | $-0.35 | not reported | not reported | |
| Q2 FY23 | not reported | $-35.80 | not reported | not reported |
Back to SGMT overview · SGMT holders · SGMT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.